Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Expert Opinion on Drug Discovery|June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma projectLucas Moreno, Hubert Caron, Birgit Geoerger, et al.
Pediatric Blood & Cancer|November 24, 2024
Management of Ganglioneuroma and Ganglioneuroblastoma Intermixed: A United Kingdom Children's Cancer and Leukaemia Group (UK CCLG) Nationwide Study ReportKatherine M Burnand, Jonathan Neville, Annita Budzanowski, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastomaSveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
JACC. Cardiovascular Interventions|June 25, 2025
15-Year Outcomes of PFO Closure in Patients With Cryptogenic Embolism: Insights From the PROLONG RegistryCarlo Gaspardone, Daniela Trabattoni, Daniele O d'Atri, et al.
Molecular Cancer|June 10, 2022
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cellsMareike Berlak, Elizabeth Tucker, Mathurin Dorel, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.
JACC. Advances|June 30, 2026
Tailoring Antiplatelet Therapy Duration After PFO Closure: Insights From the PROLONG RegistryCarlo Gaspardone, Daniela Trabattoni, Daniele O d'Atri, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaLucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
Science Translational Medicine|November 26, 2020
Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastomaKarin Straathof, Barry Flutter, Rebecca Wallace, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Pageof 12